Vitamin C for treating major depressive disorder

Vitamin C as an adjuvant for treating major depressive disorder, a randomized placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201312263930N31

Enrollment

Registered

2014-07-05

Start date

2013-09-17

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive disorder. Depressive episode

Interventions

Intervention 1: Citalopram (up to 60 mg/day) plus vitamin C (1500mg/day) for 8 weeks. Intervention 2: Citalopram (up to 60mg/day) plus placebo for 8 weeks.

Treatment - Drugs

Placebo

Citalopram (up to 60 mg/day) plus vitamin C (1500mg/day) for 8 weeks

Citalopram (up to 60mg/day) plus placebo for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 18 to 65 years old, bother gender, diagnosed with major depressive disorder using DSM-IV diagnostic criteria. Exclusion criteria: serious uncontrolled medical conditions such as hypothyroidism, bipolar mood disorder, pregnancy, depression due to a general medical condition, and hypersensitivity to vitamin C.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: baseline, week 2, week 4, and week 8. Method of measurement: Hamilton Depression Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Ghanizadeh

Shiraz University of Medical sciences

ghanizad@sina.tums.ac.ir+98 71 1627 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 18, 2026